In patients with acute coronary syndrome (ACS) receiving percutaneous coronary intervention (PCI), a potent P2Y12 inhibitor–based dual antiplatelet therapy (DAPT) is currently recommended as standard therapy.
1 However, the benefits of potent P2Y12 inhibitors on ischemic outcomes come at the cost of increased bleeding risk.
2,3 Considering that bleeding events are associated with a higher risk of mortality, we should not overlook the bleeding risk when deciding on the DAPT strategy.
4 In a recent randomized trial,
5 a de-escalation strategy of antiplatelet therapy by reducing the dose of prasugrel at 1 month post-PCI reduced net adverse clinical outcomes compared with maintaining the conventional dose of prasugrel. The benefit was driven by a significant reduction of bleeding without any increase in ischemic events. However, whether such benefits are similarly observed in those receiving complex PCI is unknown.